Showing results (101-110 of 137) with videos related to

Sort By:
Pageof 14
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 29, 2024
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer PatientsDianne Bosch, Kim J M van der Velden, Irma M Oving, et al.
Clinical Genitourinary Cancer|December 1, 2021
Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alfons J M van den Eertwegh, et al.
Clinical Genitourinary Cancer|March 13, 2025
Learning From Evidence: Changes in Real-World Use of Second Androgen Receptor Targeted Treatments in Metastatic Castration-Resistant Prostate Cancer (mCRPC)Dianne Bosch, Kim J M van der Velden, Tom Belleman, et al.
BJU International|September 2, 2025
Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancerMichiel Vlaming, Wouter Koole, R Jeroen A van Moorselaar, et al.
Prostate Cancer and Prostatic Diseases|July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancerBastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
Future Oncology (London, England)|May 30, 2020
Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancerMalou Cp Kuppen, Hans M Westgeest, Maarten J van der Doelen, et al.
Cancers|January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective StudyAmina Banda, Bastiaan M Privé, Youssra Allach, et al.
Nature Communications|November 22, 2019
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impactLisanne F van Dessel, Job van Riet, Minke Smits, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancerHarm Westdorp, Jeroen H A Creemers, Inge M van Oort, et al.
European Urology Focus|May 5, 2020
Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer RegistryJessica C L Notohardjo, Malou C P Kuppen, Hans M Westgeest, et al.
Pageof 14